Hikal (NSEI:HIKAL) - Prezzo delle azioni, notizie e analisi

HIKAL Panoramica delle azioni

Hikal Limited, insieme alle sue consociate, produce e vende vari intermedi chimici, specialità chimiche e ingredienti farmaceutici attivi a società farmaceutiche, di salute animale, biotecnologiche, di protezione delle colture e di specialità chimiche in India, Stati Uniti, Canada, Europa, Sud-Est asiatico e a livello internazionale. Maggiori dettagli

HIKAL analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	4/6
Prestazioni passate	1/6
Salute finanziaria	4/6
Dividendi	4/6

Premi

Si prevede che gli utili cresceranno del 49.2% all'anno

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili

Andamento instabile dei dividendi

Hikal Limited Concorrenti

Jeena Sikho Lifecare

NSEI:JSLL

₹47.7b

Aarti Pharmalabs

NSEI:AARTIPHARM

₹57.6b

Gufic Biosciences

BSE:509079

₹42.2b

Aarti Drugs

BSE:524348

₹42.3b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Hikal
Prezzi storici delle azioni
Prezzo attuale dell'azione	₹393.00
Massimo di 52 settimane	₹416.95
Minimo di 52 settimane	₹260.30
Beta	1.25
1Variazione di 1 mese	3.71%
Variazione a 3 mesi	20.11%
Variazione di 1 anno	45.69%
3Variazione a 3 anni	-25.94%
Variazione a 5 anni	254.37%
Variazione dall'IPO	2,604.13%

Notizie e aggiornamenti recenti

Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 15

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Sep 13

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Sep 11

Recent updates

Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 15

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Sep 13

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Sep 11

Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)

Sep 16

Calculating The Fair Value Of Hikal Limited (NSE:HIKAL)

Mar 18

Hikal (NSE:HIKAL) Is Increasing Its Dividend To ₹1.20

Feb 16

Is Hikal (NSE:HIKAL) Using Too Much Debt?

Jan 13

With EPS Growth And More, Hikal (NSE:HIKAL) Is Interesting

Jun 01

We Think Hikal (NSE:HIKAL) Can Stay On Top Of Its Debt

May 17

An Intrinsic Calculation For Hikal Limited (NSE:HIKAL) Suggests It's 25% Undervalued

Mar 23

Does Hikal Limited (NSE:HIKAL) Have A Place In Your Dividend Portfolio?

Mar 10

If You Like EPS Growth Then Check Out Hikal (NSE:HIKAL) Before It's Too Late

Feb 23

Be Sure To Check Out Hikal Limited (NSE:HIKAL) Before It Goes Ex-Dividend

Feb 10

Rendimenti per gli azionisti

	HIKAL	IN Pharmaceuticals	IN Mercato
7D	2.2%	-1.8%	-1.8%
1Y	45.7%	41.2%	27.2%

Ritorno vs Industria: HIKAL ha superato il Indian Pharmaceuticals che ha restituito 41.2 % nell'ultimo anno.

Rendimento vs Mercato: HIKAL ha superato il mercato Indian che ha restituito 27.2 % nell'ultimo anno.

Volatilità dei prezzi

Is HIKAL's price volatile compared to industry and market?
HIKAL volatility
HIKAL Average Weekly Movement	5.9%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.2%
10% least volatile stocks in IN Market	4.0%

Prezzo delle azioni stabile: HIKAL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di HIKAL è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1988	2,061	Sameer Hiremath	www.hikal.com

Hikal Limited, insieme alle sue consociate, produce e vende vari intermedi chimici, specialità chimiche e principi attivi farmaceutici a società farmaceutiche, di salute animale, biotecnologiche, di protezione delle colture e di specialità chimiche in India, Stati Uniti, Canada, Europa, Sud-Est asiatico e a livello internazionale. L'azienda opera attraverso due segmenti, Pharmaceuticals e Crop Protection. Il segmento Pharmaceuticals produce ingredienti farmaceutici attivi (API).

Hikal Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Hikal con la sua capitalizzazione di mercato?
HIKAL statistiche fondamentali
Capitalizzazione di mercato	₹48.36b
Guadagni(TTM)	₹736.02m
Ricavi(TTM)	₹18.21b

65.7x

Rapporto P/E

2.7x

Rapporto P/S

HIKAL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HIKAL Conto economico (TTM)
Ricavi	₹18.21b
Costo del fatturato	₹9.02b
Profitto lordo	₹9.20b
Altre spese	₹8.46b
Guadagni	₹736.02m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	5.97
Margine lordo	50.50%
Margine di profitto netto	4.04%
Rapporto debito/patrimonio netto	64.2%

Come si è comportato HIKAL nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.3%

Rendimento attuale del dividendo

10%

Rapporto di remunerazione

HIKAL Panoramica delle azioni

Premi

Analisi del rischio

Hikal Limited Concorrenti

NSEI:JSLL

₹47.7b

NSEI:AARTIPHARM

₹57.6b

BSE:509079

₹42.2b

BSE:524348

₹42.3b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Second quarter 2025 earnings released: EPS: ₹1.48 (vs ₹1.02 in 2Q 2024)

Hikal Limited to Report Q2, 2025 Results on Nov 12, 2024

Hikal Limited Approves Interim Dividend and Declares Final Dividend for the Financial Year 2023-24

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Second quarter 2025 earnings released: EPS: ₹1.48 (vs ₹1.02 in 2Q 2024)

Hikal Limited to Report Q2, 2025 Results on Nov 12, 2024

Hikal Limited Approves Interim Dividend and Declares Final Dividend for the Financial Year 2023-24

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Upcoming dividend of ₹0.60 per share

Hikal Limited, Annual General Meeting, Sep 17, 2024

Hikal Limited, Annual General Meeting, Sep 17, 2024

Hikal Limited Announces Management Changes

Price target increased by 14% to ₹398

First quarter 2025 earnings released: EPS: ₹0.41 (vs ₹0.56 in 1Q 2024)

Hikal Limited to Report Q1, 2025 Results on Aug 01, 2024

Hikal Limited's (NSE:HIKAL) Popularity With Investors Is Clear

Hikal Limited Approves Board Changes

New major risk - Revenue and earnings growth

Full year 2024 earnings released: EPS: ₹5.64 (vs ₹6.36 in FY 2023)

Hikal Limited Recommends Finally Dividend for the Financial Year 2023-2024

Hikal Limited to Report Q4, 2024 Results on May 09, 2024

Hikal Limited (BSE:524735) agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Hikal Limited Announces Appointment of Dharmesh Panchal as the Chief Technology Officer

Upcoming dividend of ₹0.60 per share at 0.4% yield

Dividend of ₹0.60 announced

Third quarter 2024 earnings released: EPS: ₹1.31 (vs ₹2.14 in 3Q 2023)

Hikal Limited Declares Interim Dividend for the Financial Year 2023-2024, Payable on or Before March 9, 2024

Hikal Limited Announces Resignation of B. N. Kalyani as Director

Price target increased by 9.0% to ₹350

Second quarter 2024 earnings released: EPS: ₹1.02 (vs ₹2.01 in 2Q 2023)

Hikal Limited (BSE:524735) agreed to acquire 26% stake in Fpel Ujwal Private Limited for INR 41.2 million.

Price target increased by 10.0% to ₹353

Insufficient new directors

Hikal Limited Approves the Appointment of Berjis M Desai and V. Ramachandra Kaundinya as an Independent Director

Hikal Limited to Report Q2, 2024 Results on Nov 14, 2023

Hikal Limited, Annual General Meeting, Sep 26, 2023

Hikal Limited to Report Q1, 2024 Results on Aug 08, 2023

Hikal Limited Receives Communication from the Gujarat Pollution Control Board

A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Hikal Limited Announces Recommendation of Final Dividend for the Financial Year 2022-23

Is Hikal (NSE:HIKAL) Using Too Much Debt?

Now 20% undervalued after recent price drop

Upcoming dividend of ₹0.60 per share at 0.5% yield

Hikal (NSE:HIKAL) Is Reducing Its Dividend To ₹0.60

Third quarter 2023 earnings released: EPS: ₹2.14 (vs ₹3.67 in 3Q 2022)

Hikal Limited Declares Interim Dividend for the Fiscal Year 2023, Payable on or Before March 3, 2023

Price target increased to ₹350

Investor sentiment improved over the past week

Founder & Executive Chairman recently bought ₹19m worth of stock

Hikal Limited (BSE:524735) acquired 26% stake in Radiance MH Sunrise Two Private Limited and Radiance MH Sunrise Four Private Limited for INR 46.2 million.

Investor sentiment improved over the past week

A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.01 (vs ₹3.57 in 2Q 2022)

Hikal Limited Approves Final Dividend for the Financial Year 2021-2022

Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)

Upcoming dividend of ₹0.40 per share

Insufficient new directors

Hikal Limited to Report Q3, 2023 Results on Feb 14, 2023